Spelling suggestions: "subject:"cytokinesisblock micronucleus assay"" "subject:"cytokinesisblocked micronucleus assay""
1 |
Etude des propriétés antimutagènes de l'Harpagophytum procumbens et de l'harpagoside : Généralisation aux plantes anti-inflammatoires / Antimutagenic activity of Harpagophytum procumbent and Harpagoside : Generalization to antiinflammatory plantsLuigi, Manon 16 December 2014 (has links)
Le cancer est une maladie multifactorielle dont la première étape est souvent une mutation. Il est envisageable de prévenir l'apparition de cette maladie en limitant l'apparition de mutations. Le benzo(a)pyrène et le 1-nitropyrène sont deux mutagènes et cancérogènes très répandus dans notre environnement. Ces deux composés entrainent une réponse inflammatoire chez l'homme qui à son tour induit un stress oxydant aboutissant à des mutations. L'objectif de cette étude est de rechercher l'activité antimutagène de sept plantes médicinales et de deux molécules naturelles anti-inflammatoires, avec un intérêt plus développé pour l'Harpagophytum procumbens (HP) et son principal iridoïde : l'harpagoside. Elle consiste également à vérifier si l'activité anti-inflammatoire peut être reliée à une activité antimutagène. L'activité antimutagène a été étudiée au niveau des mutations chromosomiques à l'aide du test des micronoyaux sur lymphocytes humains, et au niveau des mutations ponctuelles à l'aide du test d'Ames. Tous les extraits HP, à l'exception de l'extrait méthanolique, possèdent une activité antimutagène importante dans le test des micronoyaux, mais aucun dans le test d'Ames. Pour les six autres plantes anti-inflammatoires, plus de la moitié des extraits possèdent une activité antimutagène. Nous avons montré que l'activité antioxydante n'est pas ou peu impliquée dans l'activité antimutagène. Il est probable que d'autres mécanismes d'action soient impliqués tels que l'inhibition de l'inflammation (NF-ĸB). C'est la première fois que ce type d'études est réalisé sur des plantes possédant une activité anti-inflammatoire et plus particulièrement sur l' Harpagophytum procumbens. / Cancer is a multifactorial disease in which the first step is often a mutation in the genome. It is then possible to prevent the onset of the disease by limiting the occurrence of mutations. Benzo (a) pyrene (BaP) and 1-nitropyrene (1-NPY) are two widespread mutagens and carcinogens in our environment. These two compounds produce an inflammatory response in humans which in turn induces oxidative stress leading to gene mutations. The objective of this study was to investigate the antimutagenic activity of seven medicinal plants and two natural anti-inflammatory molecules, especially in Harpagophytum procumbens (HP) with its major iridoid: harpagoside. However, also to check whether the anti-inflammatory activity may be related to antimutagenic activity. The antimutagenic activity was investigated with chromosomal mutations using the in vitro cytokinesis-block micronucleus assay in primary cultures of human lymphocytes, and at the point mutations using the Ames test. All HP extracts, except for the methanol extract, showed a significant anti-mutagenic activity in the micronucleus test. No antimutagenic activity could be detected by the Ames assay. For the six other anti-inflammatory plants, more than half of the extracts possessed an antimutagenic activity. We have shown that the antioxidant property was not responsible for the antimutagenic activity. Thus, it is likely that other mechanisms of action are involved, such as anti-adduct mechanism, inhibition of metabolism or inhibition of inflammation (NF-ĸB). This is the first report of antimutagenic properties of anti-inflammatory plants and more particularly of the Harpagophytum procumbens.
|
2 |
Variations in radiosensitivity of breast cancer and normal breast cell lines using a 200MeV clinical proton beamDu Plessis, Peter Clark January 2018 (has links)
Thesis (MSc (Radiography))--Cape Peninsula University of Technology, 2018 / Background: Breast cancer is one of the most commonly diagnosed among woman in South Africa, and a more resilient effort should be focused on treatment improvements. Worldwide, proton therapy is increasingly used as a radiation treatment alternative to photon therapy for breast cancer, mostly to decrease the risk for radiation-induced cardiovascular toxicity. This in vitro study aims to determine a better understanding of the radiosensitivity of both tumour and normal breast cell lines to clinical proton irradiation. In addition, we propose to investigate whether the increase in linear energy transfer (LET) towards the distal part of the proton beam results in an increase in relative biological effectiveness (RBE) for both cell lines. Methods: Malignant (MCF-7) and non-malignant (MCF-10A) breast cells were irradiated at different water equivalent depths in a 200 MeV proton beam at NRF iThemba LABS using a custom-made Perspex phantom: the entrance plateau, 3 points on the Bragg peak, the D80% and the D40%. A cytokinesis-block Micronucleus (CBMN) assay was performed and Micronuclei (MNi) were manually counted in binucleated cells (BNCs) using fluorescent microscopy. Reference dosimetry was carried out with a Markus chamber and irradiations were performed with a clinical proton beam generated at NRF iThemba LABS that was degraded to a R50 (half-value depths) range of 120 mm, with a field size of 10 cm x 10 cm and a 50 mm SOBP. The phantom could be adjusted to accommodate different perspex plates depending on the depth required within the proton beam. Cells were then exposed to 0.5, 1.0, 2.0, 3.0 and 4.0 Gy doses for each cell line independently and for each dose point. Results and Discussion: For the CBMN results, a program was developed on Matlab platform to calculate the 95% confidence ellipse on the co-variance parameters α and β. These values were determined by fitting the linear quadratic dose response curve to the average number of radiation induced MNi per 1000 BN cells. The ellipse region around a coordinate (the average MN frequency) for both MCF-7 and MCF-10A cells at the plateau region was defined by the mean estimate of the α-value and the β-value that were plotted on the X-axis and Y-axis respectively. The ratio of the two parameters, α/β, is a measure of the impact of fractionation to determine the biological effective dose. In fractionated proton therapy, the MCF10A cells will repair less between two fractions compared to the MCF7 cells. This is not an indication of therapeutic gain from a fractioned treatment protocol. For this reason, the hypofractionated stereotactic treatment protocols that can be applied with protons could be to the befit of the breast cancer patient. The above argument is based only on the radiosensitivity of the two cell lines exposed in the plateau region. Further analysis of the 95% confidence ellipse of both cell lines also showed a clear increase of the alpha value toward the distal portion of the beam and indicates an increase in energy transfer in this region. The gradual increase in α and β parameters with depth for protons for both cells is of clinical importance, since it implicates a non-homogeneous dose within the targeted area and an unwanted high dose behind the targeted area. Distal energy modulation could be investigated especially with larger breast tumours. RBE was calculated as the ratio of the dose at the different positions to the dose at the entrance plateau position (reference) to obtain an equal level of biological effect. A statistically significant difference in radiosensitivity could be observed between malignant and non-malignant cells at all positions (p<0.05). The variation in RBE was between 0.99 to 1.99 and 0.92 to 1.6 for the MCF-7 and MCF10A cell respectively. Conclusions: There is a variation in RBE along the depth-dose profile of a clinical proton beam. In addition, there is difference in radiosensitivity between the cancerous cells and the normal breast cells. While this study highlights a variation in sensitivity between cells it could be used by the modelling community to further develop biologically motivated treatment planning for proton therapy.
|
3 |
Effect of drinking water disinfection by-products in human peripheral blood lymphocytes and spermAli, Aftab H.M., Kurzawa-Zegota, Malgorzata, Najafzadeh, Mojgan, Gopalan, Rajendran C., Plewa, M.J., Anderson, Diana 26 August 2014 (has links)
No / Drinking water disinfection by-products (DBPs) are generated by the chemical disinfection of water and may pose hazards to public health. Two major classes of DBPs are found in finished drinking water: haloacetic acids (HAAs) and trihalomethanes (THMs). HAAs are formed following disinfection with chlorine, which reacts with iodide and bromide in the water. Previously the HAAs were shown to be cytotoxic, genotoxic, mutagenic, teratogenic and carcinogenic. OBJECTIVES: To determine the effect of HAAs in human somatic and germ cells and whether oxidative stress is involved in genotoxic action. In the present study both somatic and germ cells have been examined as peripheral blood lymphocytes and sperm. The effects of three HAA compounds: iodoacetic acid (IAA), bromoacetic acid (BAA) and chloroacetic acid (CAA) were investigated. After determining appropriate concentration responses, oxygen radical involvement with the antioxidants, butylated hydroxanisole (BHA) and the enzyme catalase, were investigated in the single cell gel electrophoresis (Comet) assay under alkaline conditions, >pH 13 and the micronucleus assay. In the Comet assay, BHA and catalase were able to reduce DNA damage in each cell type compared to HAA alone. In the micronucleus assay, micronuclei (MNi) were found in peripheral lymphocytes exposed to all three HAAs and catalase and BHA were in general, able to reduce MNi induction, suggesting oxygen radicals play a role in both assays. These observations are of concern to public health since both human somatic and germ cells show similar genotoxic responses.
|
Page generated in 0.087 seconds